Act Capital Management, LLC holds a focused book of 62 reported positions worth $153.1M as of Q2 2026 (disclosed Jul 29, 2026, a ~29-day 13F lag). This quarter Cerebras Systems Inc - A first appears in 13F filings (one of 3 new listings in the book), a listing rather than a purchase; they opened Tesla Inc and trimmed Krystal Biotech Inc. Their largest long position is Krystal Biotech Inc at 11% of the reported non-option book. Cloning the disclosed picks since 2021 would be +9% (+1.8%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 21.1 points over this window.
Growth of $10,000 cloning Act Capital Management, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~29 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
+1 sector below the cut, 1% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Act Capital Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Tetragon Partners GP Ltd | 8 / 62 | $393.2M |
| Sloy Dahl & Holst, LLC | 7 / 62 | $476.5M |
| Aspiring Ventures, LLC | 7 / 62 | $230.1M |
| Atreides Management, LP | 7 / 62 | $6.5B |
| Blue Owl Capital Holdings LP | 6 / 62 | $260.2M |
| Privium Fund Management B.V. | 8 / 62 | $208.9M |
| Octagon Capital Advisors LP | 6 / 62 | $412.6M |
| Doliver Advisors, LP | 8 / 62 | $161.7M |
Ranked by the share of each fund's own book sitting in the names it shares with Act Capital Management, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Krystal Biotech Inc COM | $16.7M | 45.0K | 10.9% | ▼−26% Reduced · −15K sh | |
| 2 | TG Therapeutics Inc COM | $13.8M | 251.0K | 9.0% | ▲+0.8% Added · +2K sh | |
| 3 | Abivax Sa SPONSORED ADS | $12.9M | 97.0K | 8.4% | ▲+37% Added · +26K sh | |
| 4 | Chevron Corp COM | $12.4M | 75.0K | 8.1% | —Held | |
| 5 | Exxon Mobil Corp COM | $10.7M | 78.5K | 7.0% | ▲+12% Added · +9K sh | |
| 6 | Arrowhead Pharmaceuticals Inc COM | $9.0M | 110.1K | 5.9% | ▲+33% Added · +28K sh | |
| 7 | Viking Therapeutics Inc COM | $8.2M | 209.3K | 5.3% | —Held | |
| 8 | Celcuity Inc COM | $6.5M | 62.1K | 4.2% | ▼−32% Reduced · −30K sh | |
| 9 | Nektar Therapeutics COM NEW | $6.2M | 89.3K | 4.1% | ▲+26% Added · +18K sh | |
| 10 | Tesla Inc COM | $4.5M | 10.8K | 3.0% | ▲New New position | |
| 11 | Cytokinetics Inc COM | $4.0M | 47.5K | 2.6% | ▼−26% Reduced · −17K sh | |
| 12 | Ast Spacemobile Inc COM CL A | $3.9M | 43.5K | 2.5% | ▲New New position | |
| 13 | Palvella Therapeutics Inc COM | $3.4M | 22.5K | 2.2% | ▲New New position | |
| 14 | Amazon.com Inc COM | $3.1M | 12.9K | 2.0% | ▼−61% Reduced · −20K sh | |
| 15 | Nuvation Bio Inc COM CL A | $3.0M | 520.0K | 1.9% | ▲+79% Added · +230K sh | |
| 16 | Xenon Pharmaceuticals Inc COM | $2.9M | 48.0K | 1.9% | ▲+43% Added · +15K sh | |
| 17 | Energy Transfer L P COM UT LTD PTN | $2.5M | 133.1K | 1.7% | —Held | |
| 18 | Bloom Energy Corp COM CL A | $2.3M | 7.5K | 1.5% | ▲+67% Added · +3K sh | |
| 19 | Freeport-McMoran Inc COM | $2.0M | 32.5K | 1.3% | ▼−16% Reduced · −6K sh | |
| 20 | Nebius Group NV SHS CLASS A | $1.9M | 6.8K | 1.2% | ▲New New position | |
| 21 | Alumis Inc COM | $1.5M | 51.6K | 0.9% | ▼−70% Reduced · −123K sh | |
| 22 | Ambarella Inc COM | $1.4M | 16.0K | 0.9% | ▲New New position | |
| 23 | Cerebras Systems Inc COM CL A | $1.2M | 5.6K | 0.8% | →Listed Newly reportable | |
| 24 | Definium Therapeutics Inc COM | $1.2M | 25.0K | 0.8% | ▲New New position | |
| 25 | Nokia Corp SPONSORED ADR | $1.1M | 82.0K | 0.7% | ▲New New position | |
| 26 | Kura Oncology Inc COM | $975K | 88.9K | 0.6% | ▲+20% Added · +15K sh | |
| 27 | Praxis Precision Medicines Inc COM NEW | $904K | 2.7K | 0.6% | —Held | |
| 28 | Applied Optoelectronics Inc COM | $889K | 6.0K | 0.6% | ▼−77% Reduced · −20K sh | |
| 29 | Cameco Corp COM | $856K | 8.4K | 0.6% | ▲New New position | |
| 30 | Monte Rosa Therapeutics Inc COM | $847K | 35.0K | 0.6% | ▲+56% Added · +13K sh | |
| 31 | Regenxbio Inc COM | $809K | 67.5K | 0.5% | ▲+21% Added · +12K sh | |
| 32 | Mineralys Therapeutics Inc COM | $758K | 28.1K | 0.5% | ▲New New position | |
| 33 | Grayscale Bitcoin Trust ETF SHS REP COM UT | $701K | 15.4K | 0.5% | —Held | |
| 34 | Vir Biotechnology Inc COM | $655K | 64.3K | 0.4% | —Held | |
| 35 | Palisade Bio Inc COM | $643K | 307.5K | 0.4% | ▲+19% Added · +50K sh | |
| 36 | Palantir Technologies Inc CL A | $642K | 5.5K | 0.4% | ▲New New position | |
| 37 | On Semiconductor Corp COM | $567K | 6.0K | 0.4% | ▲New New position | |
| 38 | Warrior Met Coal Inc COM | $487K | 6.0K | 0.3% | —Held | |
| 39 | Crescent Energy Company CL A COM | $442K | 45.0K | 0.3% | —Held | |
| 40 | MBX Biosciences Inc COM | $442K | 8.0K | 0.3% | ▼−11% Reduced · −1K sh | |
| 41 | Keel Infrastructure Corp COM | $428K | 74.5K | 0.3% | →Listed Newly reportable | |
| 42 | Compass Pathways PLC SPONSORED ADS | $425K | 30.0K | 0.3% | ▲+94% Added · +15K sh | |
| 43 | Corvus Pharmaceuticals Inc COM | $403K | 27.0K | 0.3% | ▲New New position | |
| 44 | Alpha Cognition Inc COM | $372K | 51.5K | 0.2% | —Held | |
| 45 | Kyverna Therapeutics Inc COM | $356K | 40.0K | 0.2% | ▲+33% Added · +10K sh | |
| 46 | Axt Inc COM | $353K | 4.9K | 0.2% | ▲New New position | |
| 47 | Infleqtion Inc COM | $333K | 25.0K | 0.2% | ▲New New position | |
| 48 | Scholar Rock Hldg Corp COM | $330K | 6.0K | 0.2% | ▼−44% Reduced · −5K sh | |
| 49 | Uipath Inc CL A | $326K | 30.0K | 0.2% | ▼−40% Reduced · −20K sh | |
| 50 | Adlai Nortye Ltd SPONSORED ADS | $311K | 27.0K | 0.2% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1442273/holdings"
Use Arkolith to show ACT CAPITAL MANAGEMENT, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Jul 29, 2026 | 29d | 62 | $153.1M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 8, 2026 | 38d | 56 | $127.2M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 59 | $123.7M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 3, 2022 | 34d | 71 | $72.5M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 43d | 78 | $71.5M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 11, 2022 | 41d | 85 | $94.5M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 3, 2022 | 34d | 92 | $138.3M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 16, 2021 | 47d | 108 | $193.0M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.